My team and I set out to test whether GLP-1 drugs medications like semaglutide (Ozempic and Wegovy) and tirzepatide (Mounjaro and Zepbound), originally developed for diabetes and then approved for obesity could do what no existing addiction treatment does: curb craving itself
For comparison, semaglutide's trials showed around 15% weight loss
Stress and Anxiety Levels in Couples who Undergo Fertility Treatment: a Review of Systematic Reviews
These medications include semaglutide (Ozempic, Wegovy), dulaglutide (Trulicity), liraglutide (Victoza, Saxenda), exenatide (Byetta, Bydureon BCise), and tirzepatide (Mounjaro, Zepbound)though tirzepatide is technically a dual GIP/GLP-1 receptor agonist
They found that many peptides helped decrease body weight while allowing participants to better maintain weight loss
More side effects: The body may reject what it cant tolerate